Global Adipose Tissue-derived Stem Cell Therapy Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Adipose Tissue-derived Stem Cell Therapy Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Adipose tissue stem cells (ASCs), known as multipotent stem cells, are most commonly used in the clinical applications in recent years.
Adipose Tissue-derived Stem Cell Therapy report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Adipose Tissue-derived Stem Cell Therapy market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Therapeutic Application and Research Application are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Adipose Tissue-derived Stem Cell Therapy industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Adipose Tissue-derived Stem Cell Therapy key companies include AlloCure, Antria, Celgene Corporation, Cellleris, Corestem, Cytori Therapeutics, Intrexon, Mesoblast and Pluristem Therapeutics, etc. AlloCure, Antria, Celgene Corporation are top 3 players and held % share in total in 2022.
Adipose Tissue-derived Stem Cell Therapy can be divided into Autologous Stem Cells and Allogeneic Stem Cells, etc. Autologous Stem Cells is the mainstream product in the market, accounting for % share globally in 2022.
Adipose Tissue-derived Stem Cell Therapy is widely used in various fields, such as Therapeutic Application and Research Application, etc. Therapeutic Application provides greatest supports to the Adipose Tissue-derived Stem Cell Therapy industry development. In 2022, global % share of Adipose Tissue-derived Stem Cell Therapy went into Therapeutic Application filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Adipose Tissue-derived Stem Cell Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
AlloCure
Antria
Celgene Corporation
Cellleris
Corestem
Cytori Therapeutics
Intrexon
Mesoblast
Pluristem Therapeutics
Tissue Genesis
BioRestorative Therapies
Celltex Therapeutics Corporation
iXCells Biotechnologies
Pluristem Therapeutics
Cyagen
Lonza
Segment by Type
Autologous Stem Cells
Allogeneic Stem Cells
Therapeutic Application
Research Application
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Adipose Tissue-derived Stem Cell Therapy market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Adipose Tissue-derived Stem Cell Therapy introduction, etc. Adipose Tissue-derived Stem Cell Therapy Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Adipose Tissue-derived Stem Cell Therapy market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Adipose Tissue-derived Stem Cell Therapy report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Adipose Tissue-derived Stem Cell Therapy market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Therapeutic Application and Research Application are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Adipose Tissue-derived Stem Cell Therapy industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Adipose Tissue-derived Stem Cell Therapy key companies include AlloCure, Antria, Celgene Corporation, Cellleris, Corestem, Cytori Therapeutics, Intrexon, Mesoblast and Pluristem Therapeutics, etc. AlloCure, Antria, Celgene Corporation are top 3 players and held % share in total in 2022.
Adipose Tissue-derived Stem Cell Therapy can be divided into Autologous Stem Cells and Allogeneic Stem Cells, etc. Autologous Stem Cells is the mainstream product in the market, accounting for % share globally in 2022.
Adipose Tissue-derived Stem Cell Therapy is widely used in various fields, such as Therapeutic Application and Research Application, etc. Therapeutic Application provides greatest supports to the Adipose Tissue-derived Stem Cell Therapy industry development. In 2022, global % share of Adipose Tissue-derived Stem Cell Therapy went into Therapeutic Application filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Adipose Tissue-derived Stem Cell Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
AlloCure
Antria
Celgene Corporation
Cellleris
Corestem
Cytori Therapeutics
Intrexon
Mesoblast
Pluristem Therapeutics
Tissue Genesis
BioRestorative Therapies
Celltex Therapeutics Corporation
iXCells Biotechnologies
Pluristem Therapeutics
Cyagen
Lonza
Segment by Type
Autologous Stem Cells
Allogeneic Stem Cells
Segment by Application
Therapeutic Application
Research Application
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Adipose Tissue-derived Stem Cell Therapy market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Adipose Tissue-derived Stem Cell Therapy introduction, etc. Adipose Tissue-derived Stem Cell Therapy Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Adipose Tissue-derived Stem Cell Therapy market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices